Recurrent stroke prediction by applying a stroke polygenic risk score in the Japanese population

4 Naoki Kojima (MSc)¹, Masaru Koido (PhD)¹, Yunye He (PhD)¹, Yuka Shimmori (MSc)¹,

- 5 Tsuyoshi Hachiya (PhD)¹, BioBank Japan, Stéphanie Debette (MD, PhD)^{2,3}, Yoichiro Kamatani $(MD, PhD)^1$
-
- 1. Laboratory of Complex Trait Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
- 2. Bordeaux Population Health Research Center, University of Bordeaux, Inserm, UMR 1219, Bordeaux, France.
- 3. Department of Neurology, Institute for Neurodegenerative Diseases, CHU de Bordeaux,
- Bordeaux, France.
-
- **Short title:** Recurrent stroke prediction by PRS
-
- **Corresponding author:**
- Yoichiro Kamatani¹
- Address: 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639 Japan
- Email: kamatani.yoichiro@edu.k.u-tokyo.ac.jp
-
- **Total word count of the manuscript (including Title Page, Abstract, Text, References,**
- **Tables, and Figures Legends):** 6306
-

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Background

 Recently, various polygenic risk score (PRS)-based methods were developed to improve stroke prediction. However, current PRSs (including cross-ancestry PRS) poorly predict recurrent stroke. Here, we aimed to determine whether the best PRS for Japanese individuals can also predict stroke recurrence in this population by extensively comparing the methods and maximizing the predictive performance for stroke onset.

Methods

36 We used data from the BioBank Japan (BBJ) $1st$ cohort (n=179,938) to derive and optimize the PRSs using a 10-fold cross-validation. We integrated the optimized PRSs for multiple traits, such as vascular risk factors and stroke subtypes to generate a single PRS using the 39 meta-scoring approach (metaGRS). We used an independent BBJ $2nd$ cohort (n=41,929) as a test sample to evaluate the association of the metaGRS with stroke and recurrent stroke.

Results

 We analyzed recurrent stroke cases (n=174) and non-recurrent stroke controls (n=1,153) 44 among subjects within the BBJ 2^{nd} cohort. After adjusting for known risk factors, metaGRS was associated with stroke recurrence (adjusted OR per SD 1.18 [95% CI: 1.00–1.39, p=0.044]), although no significant correlation was observed with the published PRSs. We administered three distinct tests to consider the potential index event bias; however, the outcomes derived from these examinations did not provide any significant indication of the influence of index event bias. The high metaGRS group without a history of hypertension had a higher risk of stroke recurrence than that of the low metaGRS group (adjusted OR 2.24 [95% CI: 1.07–4.66, p=0.032]). However, this association was weak in the hypertension

group (adjusted OR 1.21 [95% CI: 0.69–2.13, p=0.50]).

Conclusions

 The metaGRS developed in a Japanese cohort predicted stroke recurrence in an independent cohort of patients. In particular, it predicted an increased risk of recurrence among stroke patients without hypertension. These findings provide clues for additional genetic risk stratification and help in developing personalized strategies for stroke recurrence prevention.

Keywords: recurrent stroke, stroke, polygenic risk score, LDpred2, risk factor, index event

bias, hypertension, metaGRS

Non-standard abbreviations and acronyms

- PRS polygenic risk score
- P+T pruning and thresholding
- BBJ BioBank Japan
- 66 BBJ1 BBJ $1st$ cohort
- 67 BBJ2 BBJ 2nd cohort
- ToMMo Tohoku Medical Megabank
- AIS all ischemic stroke
- IPW inverse probability weighting
- LD linkage disequilibrium
- GWAS genome-wide association study
- PC principal component
- IPW inverse probability weight
- AUC area under the curve
- LAS large artery stroke
- SVS small vessel stroke
- CES cardioembolic stroke
- TIS transient ischemic attack
- HWE Hardy-Weinberg equilibrium
- WGS whole genome sequencing
- MI myocardial infarction
- 83 SAP stable angina pectoris
- AP unstable angina pectoris
- AF atrial fibrillation
- DM diabetes mellitus

97 **Introduction**

98

99 Stroke is a major cause of mortality in Japan, with $56,000$ deaths reported in 2020 .¹ The 100 conventional risk factors for stroke include hypertension, high waist-to-hip ratio, smoking, 101 cardiac causes, dyslipidemia, and diabetes mellitus.² In Japan, the stroke recurrence rate is up 102 to 30–50% during 5-10 years of follow-up after the first stroke.^{3,4} Accordingly, it will be 103 medically beneficial to stratify high-risk groups for recurrent stroke among those who have 104 experienced a stroke to potentially generate more intensive secondary prevention strategies 105 than current recommendations.

 Genome-wide association studies (GWAS) have identified many disease-susceptibility 107 variants associated with complex traits.⁵ A polygenic risk score (PRS) is the weighted summation of the individual genetic effects of these variants. Its weighting strategy varies depending on the construction method; traditionally, only significant variants are used in developing this score. The recently developed PRS methods involve non-significant variants and updated effect weights and consider the linkage disequilibrium (LD) structure. The 112 development of PRS methods has helped stratify high-risk groups for complex traits, $6-11$ 113 including stroke.¹²

114 Polygenic risk scores developed using the 32 genome-wide significant ($p < 5.0 \times 10^{-8}$) variants 115 or 90 marginally associated (p <1.0×10⁻⁵) variants (PRS₉₀) from the MEGASTROKE study¹² 116 are associated with stroke onset in subjects of European ancestry.^{12,13} The meta-scoring PRS 117 approach (metaGRS) includes 3.2 million variants by combining PRSs for stroke subtypes, 118 risk factors, and comorbidities by adjusting the effect weight via elastic-net logistic 119 regression; this approach has an improved predictive performance for stroke compared to 120 that of PRS₉₀.¹⁴ MetaGRS can predict stroke incidence independent of environmental factors 121 and could help motivate individuals with high genetic risk to make lifestyle changes for

122 stroke prevention (although not yet implemented in clinical practice outside a research 123 setting).¹⁵ The PRS shows reduced transferability between populations. Additionally, a PRS 124 developed using various variants derived from Japanese GWAS successfully predicted stroke 125 onset in the Japanese population.^{16,17} Most recently, the GIGASTROKE study proposed an 126 integrated PRS approach among PRSs derived from populations of multiple ancestries using 127 the metaGRS framework (iPGS), which showed a better predictive ability than the 128 MEGASTROKE European or East Asian PRS.¹⁸ However, the PRS did not successfully 129 predict stroke recurrence; for example, PRS₃₂ and iPGS did not significantly predict stroke 130 recurrence after adjusting for clinical comorbidities, with notably smaller effect sizes than for 131 non-recurrent stroke.^{12,18} Furthermore, the potential effect of index event (also known as 132 "collider") bias that may distort the association of PRS was suspected.^{19,20}

 The optimal method to improve the predictive accuracy of PRS depends on the population-134 and trait-specific genetic architecture.²¹⁻³⁰ Therefore, we compared different PRS methods and determined whether the best PRS can predict the onset of recurrent stroke in a Japanese population.

137

Methods

 The workflow of this study is shown in Figure 1. This article follows the TRIPOD (Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis) reporting guidelines.

Study subjects and quality control

 BioBank Japan (BBJ) involves physicians diagnosing all ischemic stroke (AIS) cases at the collaborating hospitals. BBJ was established in 2003 and recruited 267,000 patients from 12 147 medical institutions (66 hospitals) in two phases.^{31–33} The recruited patients had at least one of the 51 primarily multifactorial (common) diseases, which accounted for 440,000 cases. 149 We used BBJ 1st cohort (BBJ1) data to derive PRSs and available independent BBJ 2^{nd} cohort (BBJ2) data to evaluate the performance of PRSs in predicting AIS and recurrent AIS. Recurrent AIS information was unavailable for the BBJ1 data. In BBJ2, any AIS cases (n=1,470), AIS-free controls (n=40,459), recurrent AIS cases (n=174), and non-recurrent AIS controls (n=1,153) were available. The mean duration from the first episode of AIS onset to recurrent AIS onset was 4.88 years. Detailed sample characteristics are listed in Supplementary Methods and Table 1.

 This study was approved by the ethics committee of the Institute of Medical Science, the University of Tokyo, Japan. Quality control, pre-phasing, and genotype imputation were 158 conducted using PLINK(v2.0), $34-37$ Eagle (v2.4.1), and Minimac4 (v1.0.2), respectively. The detailed processes are presented in the Supplementary Methods.

Constructing PRSs for AIS

 Unbiased PRSs were obtained by applying a 10-fold cross-validation to select the model and 163 optimize the parameters. $26,38$ Briefly, BBJ1 samples were randomly split into ten equal-sized

 subsamples. We retained one subsample for validation and the others for training. We repeated this process 10 times, with each of the ten subsamples used exactly once for validation. A GWAS was conducted on the training set in each iteration, adjusted for age, sex, and the first 10 principal components (PCs) via Firth logistic regression using PLINK $(v.2.0)^{34}$

 We obtained the weights of variants for PRS from the GWAS summary statistics of the 170 training set using five PRS methods—P+T (PLINK $(v.1.9)^{35}$ for clumping), LDpred2,³⁹ 171 Lassosum2,⁴⁰ (LDpred2 and Lassosum2 by bigsnpr package (v.1.7.2) in R (v.3.5.0)), PRS-CS $(v.1.0.0),$ ⁴¹ and PRS-CSx $(v.1.0.0).$ ⁴² The PRS-CSx integrated BBJ1 with the European stroke GWAS summary statistics (MEGASTROKE; the largest study available at this study 174 design)⁴³ by learning an optimal linear combination. We used combinations of parameters for P+T (1,224 parameters), LDpred2 (126 parameters), Lassosum2 (200 parameters), PRS-CS (9 parameters), and PRS-CSx (9 parameters), as described in the Supplementary Methods.

177 Subsequently, the PRSs for the validation sample were calculated using the weights obtained 178 from the training samples. The accuracy for predicting AIS cases was evaluated from 179 Nagelkerke's R^2 (simply " R^{2} " from this point onwards)^{29,44} after adjusting for age, sex, and 180 the first 10 PCs. We calculated the mean R^2 over 10 cross-validation results for each method 181 with each parameter after a 10-fold cross-validation. We chose the method and parameters 182 that maximized incremental R^2 (PRS_{AIS}) among these PRSs.

183 We further integrated the PRS_{AIS} with PRSs of vascular risk factors, such as stroke subtypes and comorbid diseases presence, using the elastic net framework to construct a metaGRS using the glmnet package (v.4.1.3) in R (v.4.1.0). Nine binary traits and eight quantitative 186 traits of vascular risk factors reported in a previous study¹⁴ are described in the Supplementary Methods. Binary traits were determined by conducting GWAS and attempting to obtain unbiased weights using cross-validations. The effect weights from the derivation

 sample every 17 traits were calculated using PRS-CS-auto since it did not require an independent validation sample set for parameter optimization and performed well for various 191 traits.^{21,26,39,41,45} Subsequently, we used a validation sample to calculate the weight of AIS and the 17-trait PRSs to predict AIS using elastic-net logistic regression. We conducted a 10- fold cross-validation and used the mean weight for testing. 194 We used PLINK $(v2.0)^{34}$ to calculate the individual PRS by aggregating the effect estimates multiplied by each imputed dosage into a single score per person.

Risk factors

198 The following seven risk factors that were previously utilized as covariates¹² were used as covariates for testing: hypertension (systolic blood pressure>140 mmHg, diastolic blood pressure>90 mmHg, or hypertension history), hyperlipidemia, diabetes (all types), smoking (current smoker), vascular disease (myocardial infarction, peripheral artery disease, stable angina pectoris, and unstable angina pectoris), congestive heart failure, and atrial fibrillation (including atrial flutter). A sample was considered to have a risk factor status if it had that status at enrollment or from historical records (Tables 1 and S1).

Assessment of the association of PRS with AIS and AIS recurrence

 We used a single selected method with optimized parameters and calculated the metaGRS in independent testing sample sets. We used a logistic regression model to assess the association of the PRS using the two case-control settings for AIS (any-AIS versus AIS-free controls) and AIS recurrence (recurrent AIS versus non-recurrent AIS). We also applied two other combinations of case-controls: recurrent AIS versus AIS-free controls and non-recurrent AIS versus AIS-free controls (Figure 1). Furthermore, we examined additional PRS contributions of the seven risk factors to predictive accuracy and discriminative performance using the

214 values of R^2 and area under the curve (AUC), according to our previous studies.^{14,46}

215 Additionally, we evaluated the performance of the following PRSs derived from other 216 milestone studies for stroke prediction: 32 genome-wide significant variants (for any stroke, 217 ischemic stroke, or ischemic stroke subtypes) from the MEGASTROKE cross-ancestry study 218 of 524,354 individuals (PRS_{32}) ,⁴³ 89 genome-wide significant variants of 1,614,080 multi-219 population individuals (PRS_{89}) , and $6,010,730$ variants of the East Asian PRS developed 220 from 9,809 individuals $(iPGS_{EAS})$,¹⁸ both from the GIGASTROKE study. The PRS 221 calculation process is described in the Supplementary Methods.

222

223 **Considering potential index event bias**

224 An index event bias may be induced when the samples are only selected from cases. ⁴⁷ We 225 evaluated the extent to which the index event bias affected our results since we used case-226 only samples in this study. The association of PRSs with recurrent AIS was evaluated after 227 adjusting for seven risk factors, in addition to age, sex, and the first 10 PCs. Adjusting for 228 such confounding bias will not be enough to eliminate bias for a recurrence association 229 study.⁴⁸ Therefore, we sought to mitigate a potential index event bias by applying three 230 distinct methodologies.^{48,49} First, we utilized linear and logistic regression models to assess 231 the relationships between metaGRS and covariates within the any-AIS case (n=1,327) and 232 AIS-free control groups (n=40,459). Initially, we did not adjust for age, sex, the seven risk 233 factors, or the first 10 PCs. Subsequently, we observed the distributions of covariate values 234 across the metaGRS quintiles. We performed statistical tests to detect heterogeneity in the 235 estimates between the prevalent case and control groups, following the methodology of a 236 prior study.^{19,50} Second, we refined our analysis by adjusting for associations between 237 metaGRS and AIS recurrence while considering the differential effects of covariates, 238 according to a previous method.¹⁹ Finally, we applied the inverse probability weighted (IPW)

239 approach⁴⁷ to comprehensively account for index event bias. Collectively, these analytical approaches were adopted to enhance the validity of our findings.

Association of metaGRS and AIS recurrence in patients with/without hypertension

 Logistic regression was conducted in subgroups with and without hypertension and metaGRS 244 tertiles among recurrent AIS cases (with hypertension $n=107$, without hypertension $n=67$) and non-recurrent AIS controls (with hypertension n=731, without hypertension n=422) to assess the relationship between the PRS and the risk of AIS recurrence. The low metaGRS tertile was set as the reference group and adjusted for age, sex, and the first 10 PCs.

Statistical analysis

 The mean with standard deviation (SD) or proportion of factors was reported for the baseline 251 characteristics of testing samples. The incremental value (R^2 or AUC) was estimated from the differences between patients with and without PRSs of the fitted values of age, sex, first 253 10 PCs, and seven risk factors^{48,57,58} and calculated as the 95% confidence interval. The pROC package (v.1.18.0) in R was used to determine the discriminative ability of the AUC. The IPW package (v.1.2) in R was used for the IPW approach. R (v. 3.5.0) was used to 256 perform logistic regression to calculate \mathbb{R}^2 , Pearson's correlation coefficient, and linear 257 regression. All statistical tests were two-sided. The significance level was set at $p = 0.05$.

-
-

Results

Derivation of effect weight

 The imputed genotype data of 17,621 AIS cases and 162,317 controls without an AIS diagnosis were used for 9,622,629 autosomal variants after implementing quality control of 265 the BBJ1 dataset (Tables S2-S4).

 We conducted a 10-fold cross-validation to adjust the parameters and select the best PRS associated with AIS. We performed GWAS 10 times on 90% of the randomly selected BBJ1 268 dataset (training data). We successfully detected previously reported^{43,51} signals in each 269 dataset (p<5×10⁻⁸), including *SH3PXD2A*, *CCDC63* (eight times), *CUX2*, and *LINC02356* (every time) (Figure S1, Table S5).

 We confirmed some expected characteristics of each PRS method (such as low accuracy) using only genome-wide significant variants (Tables S6–10 and Supplementary Notes). The 273 mean incremental R^2 values of each scoring method with the best-performed parameters were 0.0038 (95% CI: 0.0030–0.0046), 0.00443 (95% CI: 0.0035–0.0054), 0.0039 (95% CI: 0.0030–0.0048), 0.00441 (95% CI: 0.0036–0.0053), and 0.0037 (95% CI: 0.0031–0.0042) for P+T, LDpred2, Lassosum2, PRS-CS, and PRS-CSx, respectively (Table 2). We chose 277 LDpred2 with the parameter set of ρ -value = 0.0056, a heritability-value = $1.0 \times h^2$ _{LDSC}, 278 where h^{2} _{LDSC} is the heritability estimate from the constrained LD score regression⁵², and a 279 no-sparse model for subsequent analyses, since it showed the best mean incremental R^2 value among the five methods.

 We observed an average number of nonzero weights for 8.4 traits after computing the metaGRS via elastic net regularization 10 times (10-fold). The metaGRS weight of AIS was highest (mean=0.123, SD=0.026), followed by diastolic blood pressure (mean=0.039, SD=0.039), atrial fibrillation (mean=0.023, SD=0.024), and myocardial infarction (mean=0.018, SD=0.025) (Figure S2 and Table S11). Only the triglyceride weights were zero at all 10 measurements among the 18 traits included in the metaGRS calculation. The number of variants used for metaGRS was 1,014,026; a total of 1,011,847 variants (99.8%) remained after matching with the BBJ2 dataset.

Association of metaGRS with AIS cases and recurrent AIS

 We used the imputed genotype data of 1,470 AIS cases and 40,459 controls without a diagnosis of AIS for 59,387,070 variants from the BBJ2 dataset to test the association of metaGRS with AIS and AIS recurrence. The AIS case-only sample of the BBJ2 was used to analyze AIS recurrence. Table 1 presents the characteristics of the test samples.

 MetaGRS was associated with AIS diagnosis after adjusting for age, sex, first 10 PCs, and 296 seven risk factors (adjusted OR, 1.21 [95% CI: 1.15–1.27, p=2.89×10⁻¹²]), as previously 297 reported.^{14,18} MetaGRS was also associated with AIS recurrence compared with recurrence- free AIS (adjusted OR 1.18 [95% CI: 1.00–1.39, p=0.044]; Table 3 and Figure S3). MetaGRS showed stronger association when comparing recurrent AIS with AIS-free controls (adjusted 300 OR 1.37 [95% CI: 1.18–1.59, p=5.35×10⁻⁵]; Table S12).

 The contribution of the metaGRS and traditional risk factors showed an AIS prediction 302 accuracy with an R^2 value of 0.06 and an AUC of 0.689 after constructing the baseline model using age, sex, the first 10 PCs, and seven risk factors. The incremental AUCs were 0.0087 and 0.0123 for AIS and AIS recurrence, respectively when metaGRS was added to the baseline model (Table 3). In our dataset, clinical risk factors (including hypertension) were related to AIS diagnosis but were insignificantly associated with AIS recurrence (Table S1).

 We assessed the prediction performance of previously developed PRSs for AIS and AIS recurrence in our dataset. After matching with the BBJ2 dataset (Supplementary Methods),

27, 84, and 5,756,652 variants remained in $PRS₃₂$, $PRS₈₉$, and iPGS, respectively. We

 confirmed their association with AIS diagnosis; adjusted ORs were 1.11 [95% CI: 1.06–1.17, 311 p=4.23×10⁻⁵], 1.08 [95% CI: 1.03–1.14, p=2.96×10⁻³], and 1.26 [95% CI: 1.20–1.33, $p=1.24\times10^{-17}$ for PRS₃₂, PRS₈₉, and iPGS, respectively (Table 3, Figure S3); however, a significant association was not observed between PRSs and AIS recurrence (p-values of 0.41, 0.054, and 0.37, respectively; Table 3 and Figure S3). Our Japanese optimized metaGRS was the only PRS significantly associated with AIS recurrence in this study.

Analyzing for potential index event bias

 We observed the values of covariates at the AIS-free control group and any-AIS case group in each quintile. We did not find any significant heterogeneous relationships between the covariates and the metaGRS in terms of regression estimates in the prevalent case and 321 control samples (p>0.05, Table S13).

 We used three different variable models—i) age and sex; ii) age, sex, and seven risk factors; and iii) age, sex, the first 10 PCs, and seven risk factors—to determine the association between metaGRS and recurrent AIS; none of these confounders significantly influenced our results (Figure S4).

 We compared the association results of IPW adjusted (accounting for index event bias) with those of non-adjusted IPW (accounting for confounding bias). The results remained almost unchanged, but the 95% confidence intervals overlapped (Figure S5). A comparison of the three distinct models did not indicate an effect of index event bias.

Association of metaGRS and AIS recurrence in patients with/without hypertension

 We divided the test sample into subgroups according to the presence or absence of a history of hypertension and evaluated the risk effect of the metaGRS tertile. The high metaGRS group without a history of hypertension showed a higher risk effect for AIS recurrence

Discussion

 We successfully examined the association between recurrent AIS and our best model PRS (metaGRS using LDpred2); the adjusted OR was 1.18 for each unit of SD increase in PRS. Our metaGRS showed stronger (adjusted OR per SD=1.37) association when comparing recurrent AIS with AIS-free controls. Furthermore, a high PRS was associated with AIS recurrence particularly in groups without a history of hypertension (OR of the top vs. bottom metaGRS tertile=2.24). These results are consistent with the result of a previous study wherein the stroke prediction accuracy of the PRS was high in the group with low 351 CHA2DS2-VASc scores.¹² These results indicate the utility of the PRS in developing more precise strategies to prevent AIS recurrence in individuals with a high PRS who do not have high profiles based on clinical risk factors.

 We attempted to mitigate potential index event bias since our purpose was to specifically determine the efficacy of PRS among AIS patients. It is difficult to predict and provide an accurate assessment of recurrent AIS based on genetic predisposition owing to the possible effect of index event bias leading to a distorted association in studies on recurrent 358 stroke.^{19,20,53} This study found no evidence of heterogeneous associations between covariates and the metaGRS; we did not find any evidence of a solid collider bias of known variables. By applying IPW, we confirmed that our results support the association between metaGRS and recurrent AIS.

 There are three putative reasons our metaGRS could predict AIS recurrence. First, the metaGRS algorithm combines the genetic profiles of related traits and slightly improves the performance, reaching the level of significance. Second, the performances of PRS-CS 365 (incremental R^2 =0.00441) and LDpred2 (incremental R^2 =0.00443) in our validation analysis were better than those of other traditional PRS methods, such as P+T (incremental R^2 =0.0038). This demonstrated the importance of using shrinkage estimation methods that

 consider LD to predict AIS and AIS recurrence. Third, we restricted to use only single matched ancestry throughout.

 Nevertheless, our study had several limitations. First, the sample size for recurrent AIS needs to be increased (n=174 at testing), even in the largest hospital-based biobank in Japan. Compared to our metaGRS, iPGS constructed in GIGASTROKE showed a stronger association for AIS and weaker association for AIS recurrence. Although potential discrepancies exist, both PRSs (metaGRS and iPGS) exhibit the same direction of effects and have overlapping confidence intervals (Table 3, Figure S3). Second, despite using as many covariates (age, sex, the first 10 PCs, and seven risk factors (hypertension, hyperlipidemia, diabetes mellitus, smoking, vascular disease, congestive heart failure, and atrial fibrillation)) 378 as possible based on a previous study,¹² other confounders might have affected our results. Finally, there may have been an index event bias that was not fully detected by each method that we implemented; however this risk was minimized using multiple approaches. Further studies using different sample sets (including other ancestry groups) are warranted to confirm the prediction of recurrent stroke using the PRS.

 In conclusion, our study indicated that PRS can be applied to predict AIS recurrence in addition to traditional clinical risk factors. This shows the potential utility of PRS in population-based screening and in the clinical setting. Overall, our results indicate that stratifying high-risk groups for recurrent stroke among those who have experienced a stroke could be medically beneficial and help in developing personalized strategies for recurrence prevention. Our results suggest that it might be particularly useful in patients with AIS without hypertension, although this requires confirmation in independent datasets.

Data availability

- The weights of metaGRS derived in this study will be publicly available after acceptance.
- Genotype datasets were deposited in the National Bioscience Database Center Human
- Database (BBJ1, Research ID: hum0014; BBJ2, Research ID: hum0311).
-

Source of Funding

 This research was supported by the Ministry of Education, Culture, Sports, Sciences and Technology (MEXT) of the Japanese government and the Japan Agency for Medical Research and Development (AMED) under grant nos. JP18km0605001/ JP23tm0624002 (the

BioBank Japan project), JP223fa627011 (Y.K.), and JP23tm0524003 (Y.K.).

Disclosures

Y.K. holds stock of StaGen Co, Ltd.

- **Supplementary Material**
- Supplementary Methods
- Supplementary Notes

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.06.17.24309034;](https://doi.org/10.1101/2024.06.17.24309034) this version posted June 17, 2024. The copyright holder for this preprint

- Tables S1–S15
- Figures S1–S5
-
- **References**

- 1. Ministry of Health, L. and W. Vital Statistics of Japan, https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei20/index.html. (2020).
- 2. O'Donnell, M. J. *et al.* Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. *The Lancet* **388**, 761–775 (2016).
- 3. Hata, J. *et al.* Ten year recurrence after first ever stroke in a Japanese community: The Hisayama study. *J Neurol Neurosurg Psychiatry* **76**, 368–372 (2005).
- 4. Takashima, N. *et al.* Long-term survival after stroke in 1.4 million japanese population: Shiga stroke and heart attack registry. *J Stroke* **22**, 336–344 (2020).
- 5. MacArthur, J. *et al.* The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). *Nucleic Acids Res* **45**, D896–D901 (2017).
- 6. Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of polygenic risk scores. *Nat Rev Genet* **19**, 581–590 (2018).
- 7. Khera, A. v. *et al.* Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction. *Circulation* **139**, 1593–1602 (2019).
- 8. Konuma, T. & Okada, Y. Statistical genetics and polygenic risk score for precision medicine. *Inflamm Regen* **41**, (2021).
- 9. Levin, M. G. & Rader, D. J. Polygenic Risk Scores and Coronary Artery Disease. *Circulation* 637–640 (2020) doi:10.1161/CIRCULATIONAHA.119.044770.
- 10. Plagnol, V. Polygenic score development in the era of large-scale biobanks. *Cell Genomics* **2**, 100088 (2022).
- 11. Khera, A. v. *et al.* Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nature Genetics* vol. 50 1219–1224 Preprint at https://doi.org/10.1038/s41588-018-0183-z (2018).
- 12. Marston NA *et al.* Clinical Application of A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease. *Circulation. 2021 Feb 2;143(5):470-478. doi: 10.1161/CIRCULATIONAHA.120.051927. Epub 2020 Nov 13. PMID: 33185476; PMCID: PMC7856243.* (2020).
- 13. Rutten-Jacobs, L. C. A. *et al.* Genetic risk, incident stroke, and the benefits of adhering to a healthy lifestyle: Cohort study of 306 473 UK Biobank participants. *BMJ (Online)* **363**, 1–8 (2018).
- 14. Abraham, G. *et al.* Genomic risk score offers predictive performance comparable to clinical risk factors for ischaemic stroke. *Nat Commun* **10**, 1–10 (2019).
- 15. Thomas, E. A. *et al.* Polygenic Risk, Midlife Life's Simple 7, and Lifetime Risk of Stroke. *J Am Heart Assoc* **11**, (2022).
- 16. Hachiya, T. *et al.* Genetic Predisposition to Ischemic Stroke: A Polygenic Risk Score. *Stroke* **48**, 253–258 (2017).
- 17. Hachiya, T. *et al.* Genome-wide polygenic score and the risk of ischemic stroke in a prospective cohort: The Hisayama study. *Stroke* 759–765 (2020)

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.06.17.24309034;](https://doi.org/10.1101/2024.06.17.24309034) this version posted June 17, 2024. The copyright holder for this preprint

- *Bioinformatics* **36**, 5424–5431 (2020). 40. Privé, F., Arbel, J., Aschard, H. & Vilhjálmsson, B. J. Identifying and correcting for misspecificationsin GWAS summary statistics and polygenic scores. *Human Genetics and Genomics Advances* 100136 (2022) doi:10.1016/j.xhgg.2022.100136.
- 41. Ge, T., Chen, C. Y., Ni, Y., Feng, Y. C. A. & Smoller, J. W. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat Commun* **10**, 1–10 (2019).
- 42. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat Genet* (2022) doi:10.1038/s41588-022-01054-7.
- 43. Malik, R. *et al.* Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet* **50**, 524–537 (2018).
- 44. Nagelkerke N. J. D. A Note on a General Definition of the Coefficient of Determination. *Biometrika* **78**, 691–692 (1991).
- 45. Wang, Y. *et al.* Global Biobank analyses provide lessons for developing polygenic risk scores across diverse cohorts. *Cell Genomics* **3**, (2023).
- 46. Hindy, G. *et al.* Genome-wide polygenic score, clinical risk factors, and long-term trajectories of coronary artery disease. *Arterioscler Thromb Vasc Biol* 2738–2746 (2020) doi:10.1161/ATVBAHA.120.314856.
- 47. Mitchell, R. E. *et al.* Strategies to investigate and mitigate collider bias in genetic and Mendelian randomisation studies of disease progression. *PLoS Genetics* vol. 19 Preprint at https://doi.org/10.1371/journal.pgen.1010596 (2023).
- 48. Sep, S. J., Van Kuijk, S. M. & Smits, L. J. Index event bias: Problems with eliminating the paradox. *Journal of Stroke and Cerebrovascular Diseases* vol. 23 2464 Preprint at https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.06.025 (2014).
- 49. Levine, D. A. *et al.* Smoking and mortality in stroke survivors: Can we eliminate the paradox? *Journal of Stroke and Cerebrovascular Diseases* **23**, 1282–1290 (2014).
- 50. Altman, D. G. & Bland, J. M. Interaction revisited: The difference between two estimates. *BMJ* **326**, 219 (2003).
- 51. Ishigaki, K. *et al.* Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases. *Nat Genet* **52**, 669–679 (2020).
- 52. Bulik-Sullivan, B. *et al.* LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).
- 53. Cho, S. M. J. *et al.* Genetic, sociodemographic, lifestyle, and clinical risk factors of recurrent coronary artery disease events: a population-based cohort study. *Eur Heart J* (2023) doi:10.1093/eurheartj/ehad380.
- 54. Weale, E. M. Quality control for genome-wide association studies. *Methods Mol Biol* 549 (2010) doi:10.1007/978-1-60327-367-1_19.
- 55. Akiyama, M. *et al.* Characterizing rare and low-frequency height-associated variants in the Japanese population. *Nat Commun* **10**, (2019).
- 56. Privé, F., Vilhjálmsson, B. J., Aschard, H. & Blum, M. G. B. Making the Most of Clumping and Thresholding for Polygenic Scores. *Am J Hum Genet* **105**, 1213–1221 (2019).
- 57. Chagnon, M., O'Loughlin, J., Engert, J. C., Karp, I. & Sylvestre, M. P. Missing single nucleotide polymorphisms in Genetic Risk Scores: A simulation study. *PLoS One* **13**, 1–14 (2018).
- 58. Goldstein, B. A., Yang, L., Salfati, E. & Assimes, T. L. Contemporary Considerations for Constructing a Genetic Risk Score: An Empirical Approach. *Genet Epidemiol* **39**, 439–445 (2015).
- 59. Wang, Y. *et al.* Global Biobank analyses provide lessons for developing polygenic risk

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.06.17.24309034;](https://doi.org/10.1101/2024.06.17.24309034) this version posted June 17, 2024. The copyright holder for this preprint

scores across diverse cohorts. *Cell Genomics* **3**, (2023).

- 60. Tadaka, S. *et al.* jMorp updates in 2020: Large enhancement of multi-omics data resources on the general Japanese population. *Nucleic Acids Res* **49**, D536–D544 (2021).
- 61. Restuadi, R. *et al.* Polygenic risk score analysis for amyotrophic lateral sclerosis leveraging cognitive performance, educational attainment and schizophrenia. *European Journal of Human Genetics* (2021) doi:10.1038/s41431-021-00885-y.
- 62. Turley, P. *et al.* Multi-trait analysis of genome-wide association summary statistics using MTAG. *Nat Genet* **50**, 229–237 (2018).
- 63. Maier, R. M. *et al.* Improving genetic prediction by leveraging genetic correlations among human diseases and traits. *Nat Commun* **9**, 1–17 (2018).
- 64. Ho, W. K. *et al.* European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. *Nat Commun* **11**, 1–11 (2020).
- 65. Amariuta, T. *et al.* Improving the trans-ancestry portability of polygenic risk scores by prioritizing variants in predicted cell-type-specific regulatory elements. *Nat Genet* **52**, 1346–1354 (2020).
-

580 **Tables**

581

582 **Table 1. Characteristic of the testing sample (BBJ2)**

583

585 All risk factor characteristics were derived from history and not at the time of registration. 586 Odds ratio (OR), 95% CI (95% confidence intervals, and p-values were calculated using 587 logistic regression for onset and AIS recurrence (unadjusted for other factors). *Age at AIS

594 **Table 2. Polygenic risk score performance at validation**

595

596

598 **Table 3. Polygenic risk score performance at testing**

599

PRS Method	Association tests	OR per SD [95% CI]	p-value	Incre- mental AUC	Incremental Nagelkerke R^2
MetaGRS	AIS	$1.21[1.15-1.27]$	2.89E-12	0.0087	0.0044
	Recurrence	$1.18[1.00-1.39]$	0.044	0.0123	0.0057
MEGASTROKE 27 SNVs	AIS	$1.11[1.06-1.17]$	4.23E-05	0.0033	0.0015
	Recurrence	$1.07[0.91 - 1.25]$	0.41	0.0032	0.0009
GIGASTROKE 84 SNVs	AIS	$1.08[1.03-1.14]$	2.96E-03	0.0022	0.0008
	Recurrence	$1.17[1.00-1.38]$	0.054	0.0125	0.0052
GIGASTROKE iPGS	AIS	$1.26[1.20-1.33]$	1.24E-17	0.0130	0.0066
	Recurrence	$1.08[0.91-1.27]$	0.37	0.0044	0.0011

⁶⁰⁰

 Polygenic risk score performance was evaluated using an independent testing set for AIS and recurrent AIS. We showed two main association tests; AIS (any-AIS cases vs. AIS-free controls) and AIS recurrence (recurrent AIS vs. non-recurrent AIS). Incremental AUC and R^2 603 are the differences in the values when fitting with/without PRS, along with age, sex, the first 10 PCs, and seven risk factors. Abbreviations: AIS, all ischemic strokes; OR, odds ratio; 606 AUC, area under the curve; PC, principal components; PRS, polygenic risk score; $SD =$ standard deviation

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.06.17.24309034;](https://doi.org/10.1101/2024.06.17.24309034) this version posted June 17, 2024. The copyright holder for this preprint

Figure Legends

Figure 1. Workflow

 MEGASTROKE AIS summary statistics of European (EUR) studies were only used for PRS-CSx. 1000 Genomes Project super population samples (EAS or EUR) were used for the LD reference panel. Abbreviations: GWAS = genome-wide association study, PRS = 615 polygenic risk score, $P+T =$ pruning and thresholding, $OR =$ odds ratio, $AIS =$ all ischemic stroke, ToMMo = Tohoku Medical Megabank; LD, linkage disequilibrium.

 We used a logistic regression model to assess the association of the PRS using the two case- control settings for AIS (**A**: any-AIS vs. AIS-free controls) and AIS recurrence (**B**: recurrent AIS vs. non-recurrent AIS). We also applied two other combinations of case-controls (**C**: recurrent versus AIS-free controls and **D**: non-recurrent versus AIS-free controls).

Figure 2. Odds ratio of metaGRS tertiles with/without a history of hypertension

 Association of AIS recurrence and meta-GRS tertiles with or without a history of hypertension (HT) in the testing sample, with reference to the low metaGRS tertiles.

-
-
-
-
-
-

Supplementary Methods

Samples

BioBank Japan (BBJ) collected DNA, serum, and medical records (clinical information) with

647 consent from patients. The BBJ $1st$ cohort (BBJ1) dataset contained all ischemic stroke (AIS,

n=17,621) cases, including large artery stroke (LAS, n=981), small vessel stroke (SVS,

 n=3,108), and cardioembolic stroke (CES, n=608) cases. The patients without AIS were included as controls (n=162,317).

651 Testing involved the use of data from part of the BBJ 2^{nd} cohort (BBJ2) dataset, which contains information about AIS cases (n=1,470), including LAS (n=268), SVS (n=508), CES (n=122), and transient ischemic attack (TIA, n=105). All patients without AIS were included as controls (n=40,459). Among these cases, recurrent ischemic stroke (n=187) was used as a 655 case of recurrent AIS, which included LAS ($n=40$), SVS ($n=57$), CES ($n=11$), and transient ischemic attack (TIA, n=20). Samples with information on the first onset date and follow-up of under 30 days were excluded; AIS cases with recurrence (n=174) were set as the case group, and AIS cases without recurrence (n=1,153) remained in the control group in the testing sample.

Quality control and imputation process of BBJ1 data

 We removed variants with call rates <0.99, samples with call rates <0.98, non-East Asian samples, and sex-discordant samples. We used 939 samples whose genotypes were analyzed using whole-genome sequencing (WGS); we added an additional quality control based on the concordance rate between the genotyping array and WGS. We excluded variants with 666 concordance rates <99.5% or non-reference discordance rates ≥ 0.5 % and Hardy-Weinberg 667 equilibrium (HWE) (p <1e-6). The 10 principal components (PCs) were calculated by applying additional quality control (QC) to the BBJ1 genotyped data. We removed samples 669 from close relatives (King's cutoff > 0.0884), and 24 long LD regions,⁵⁴ including the MHC region (chr6, position 25,000,000-35,000,000), and MAF<0.01. We pruned (PLINK2 parameters: --indep-pairwise 200 50 0.20) and finally used 92,231–92,303 variants to conduct projection and calculate the first 10 PCs depending on a 10-fold sample set of the 90% BBJ1 dataset.

674 Subsequently, the datasets were phased (Eagle v2.4.1) and imputed (Minimac4 v1.0.2) using 675 the developed panel.⁵⁵ We further conducted quality control to remove variants with minor allele counts <10, close relatives (King cutoff >0.0884), and imputation r-square <0.8.

Quality control and imputation process for BBJ2 data

 We removed samples with no age/sex information, sex discrepancy, call rates <0.98, 680 heterozygosity rates with SD >4 or <- 4, from duplicate or twins (pi-hat >= 0.75), and from non-East Asian subjects. We then removed variants with a call rate <0.99, duplicate SNPs, 682 heterozygous count ≤ 5 , HWE (p $\leq 1e-6$), and allele frequency discrepancies (gap from 1000 genomes EAS >0.16). A total of 41,929 samples and 525,239 variants were analyzed.

 We applied additional quality control to the BBJ2 genotyped data to calculate the 10 PCs. We 685 removed variants in 24 long LD regions,⁵⁴ pruned them (PLINK2 parameters: --indep- pairwise 200 50 0.05), extracted close relatives (King cut-off >0.0884), and used 69,068 variants to calculate the first 10 PCs.

- We removed variants of the imputation r-squared <0.3 after phasing (Eagle v2.4.1) and 689 imputing (Minimac4 v1.0.2) the developed panel.⁵⁵ We used a lower r-square threshold for BBJ2 to reduce the number of variants unmatched with BBJ1.
-

Polygenic risk score parameters at the derivation

 Pruning and threshold used a total of 1,224 parameter combinations of three stricter imputation r-squared score thresholds {0.8, 0.9, and 0.95}, four base sizes of the clumping window {50, 100, 200, and 500}, six squared correlations of clumping {0.01, 0.05, 0.2, 0.5, 0.8, and 0.95}, and 17 p-value threshold {1e-8, 3e-8, 1e-7, 3e-7, 1e-6, 3e-6, 1e-5, 3e-5, 1e-4, 3e-4, 1e-3, 3e-3, 0.01, 0.03, 0.1, 0.3, and 1}. We used clumping windows and divided the 698 base size by the squared correlation of clumping.^{56–59} The following default parameters were 699 used for LDpred2: three heritability $\{0.7, 1, \text{ and } 1.4\} \times h_{\text{LDSC}}^2$, where h_{LDSC}^2 is the heritability 700 estimate from the constrained LD score regression,⁵² 21 ρ estimates {equally spaced on a log scale between 1e-5 and 1}, and sparse or not. The following default parameters were used for Lassosum2: 10 values of s {0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0} and 20 values of λ {equally spaced on a log scale between 0.1 and 0.001}. Regarding PRS-CS and PRS-CSx, we used slightly more extended parameters: phi {1e-7, 1e-6, 1e-5, 1e-4, 1e-3, 0.01, 0.1, 1, and auto}, than the default parameters {1e-4, 1e-3, 0.01, 0.1, 1, and auto}, because the optimized parameter in the initial trials using our dataset was the smallest (phi=1e-4) in the 707 default range. Other parameters were set to default values $(a=1, b=0.5)$.^{41,42}

Linkage disequilibrium (LD) reference

 We used the EAS superpopulation of the 1000 Genomes panel (n=504) as a LD reference for P+T clumping. For Ldpred2, Lassosum2, PRS-CS, and PRS-CSx models, we restricted our use of external LD reference panels to the HapMap 3 variants, which were also constructed from 1000 Genomes EAS. HapMap 3 variant restriction resulted in 898,456, 898,456, 985,440, and 1,076,835 variants of Ldpred2, Lassosum2, PRS-CS, and PRS-CSx, respectively. To use PRS-CSx for the EUR, we used the EUR superpopulation of the 1000 Genomes panel and its HapMap3 variants (1,016,745 variants).

Genome wide association study summary statistics for metaGRS construction

 MetaGRS was developed following a previous study¹⁴ and included nine binary and eight quantitative traits. The nine binary traits were SVS, LAS, CES, myocardial infarction (MI), stable angina pectoris (SAP), unstable angina pectoris (AP), atrial fibrillation (AF), diabetes (DM), and ever smoking (SM) from the BBJ1 dataset. Subsequently, we conducted GWAS. The number of cases and controls is listed in Table S15. Summary statistics were obtained from the jMorp website (https://jmorp.megabank.tohoku.ac.jp) and were used for eight quantitative traits—body mass index (BMI), height (HE), systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) from the Tohoku Medical Megabank 728 Project (ToMMo; 22,033 to 47,056 samples).⁶⁰

Polygenic risk score calculation from other milestone studies

 We obtained effect weights from the PGS catalog (PGS000665 and PGS002725 of 732 https://www.pgscatalog.org for PRS_{32} and $IPGS_{EAS}$, respectively) and for PRS_{89} from the 733 supplementary tables.¹⁸ We used variants that matched with the BBJ2 dataset (imputation r-734 squared > 0.3). The unmatched variants in PRS_{32} and PRS_{89} included proxy variants that showed the highest r-squared values with the index variants only from an r-squared value 736 greater than 0.3. The r-squared values were calculated using the plink -12 command³⁵ with 737 the 1000 Genome EAS as a reference.

739 **Supplementary Notes**

740

741 **Characteristics of the PRS methods during validation**

742 The following characteristics of each method were observed while testing several 743 parameters: the best mean incremental R^2 of 0.0038 was observed for the P + T method when 744 we liberalized the p-value threshold to 1 and clumped $r^2 > 0.8$, whereas it was below 0.001 745 when we used a low p-value threshold ($\leq 10^{-8}$, Table S5). For LDpred2, ρ values higher than 746 0.001 showed good performance (mean incremental R² was 0.0038 for ρ values >=0.001 747 compared to 0.0016 for *ρ* values <0.001), while heritability estimates and sparse parameters 748 made less difference (Table S6). For Lassosum2, the closer the value of parameter "s" is to 1, 749 the higher the prediction accuracy, but it wasn't the case at exactly 1. Larger lambda 750 parameters correlate with greater accuracy (mean incremental R^2 was between 0.0025 to 751 0.0039). However, the accuracy sharply decreases (mean incremental R^2 < 0.001) if the value 752 is too small (0.01) . The prediction performance was maximized when the parameters were 753 s=0.9 and lambda=0.0038 (Table S7). High and low phi values resulted in low performance 754 for PRS-CS (mean incremental R² was 0.0041 for phi= 10^{-3} , 10^{-4} , and 10^{-5} compared to 755 0.0029 for other phi parameters; Table S8). Meanwhile, PRS-CSx was relatively consistent regardless of the phi values (mean incremental R^2 was 0.0032 for phi=10⁻³, 10⁻⁴, and 10⁻⁵ 756 757 compared to 0.0028 for other phi parameters; Table S9).

758 The performance of the PRS-CS $(R^2=0.00441)$ was comparable to that of LDpred2 759 (R^2 =0.00443) in the validation analysis. Low validation predictability (incremental R^2 < 760 0.001) was observed when we restricted the p-value threshold in the P+T method to genome-761 wide significance ($p \le 5 \times 10^{-8}$). PRS-CSx improves cross-population polygenic prediction by 762 integrating GWAS summary statistics from other populations;⁶¹⁻⁶⁵ however, we could not 763 reproduce this result in our current study using PRS-CSx. Our results demonstrate the

- importance of using Bayesian methods of high-dimensional techniques in variable selection
- and shrinkage estimation considering LD (such as LDpred2 and PRS-CS) to predict AIS and
- recurrent AIS.

769 **Supplementary Figures**

770

771 **Figure S1. Genome-wide association study (GWAS) in derivation samples**

We conducted stroke GWAS using 90% of BBJ 1st cohort data as the derivation sample, using Firth logistic Firth logistic regression and PLINK (v.2.0) for each 10-fold cross-validation identification. a. Quantile-Quantile plot, b. .
ف regression and PLINK (v.2.0) for each 10-fold cross-validation identification. a. Quantile-Quantile plot, Manhattan plot, and c. genome-wide significant (p<5e-8) loci of each fold. Abbreviations: Chr = chromosome. Manhattan plot, and c. genome-wide significant (p<5e-8) loci of each fold. Abbreviations: Chr = chromosome. We conducted stroke GWAS using 90% of BBJ 1st cohort data as the derivation sample, using

773

Figure S2. Elastic net weight

 The mean weight of 10-fold elastic net regression as determined by "glmnet" in the validation sample. The X-axis shows the AS and the 17 binary and quantitative traits. Error bars represent standard deviations.

 Abbreviations: AIS, all ischemic stroke; SVS, small vessel stroke; LAS, large artery stroke; CES, cardioembolic stroke; MI, myocardial infarction; SAP, stable angina pectoris; UAP, unstable angina pectoris; AF, atrial fibrillation; DM, diabetes; SM, smoking; BMI, body mass index; HE, height; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HCL, high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation.

Figure S3. Odds ratio per SD to predict AIS and AIS recurrence

 Odds ratio per standard deviation by metaGRS and three publicly available PRS in the independent test set of AIS (case=1, 470, control=40,459) and AIS recurrence case-control set (case=174, control=1,153). Age, sex, the first 10 PCs, and seven risk factors were adjusted. Error bars represent 95% confidence intervals. The dotted line represents the point at which the ORs per SD of AIS and AIS recurrence were equal. Abbreviations: OR, odds ratio; AIS, all ischemic stroke; PRS, polygenic risk score; PC, principal component; SD, standard deviation.

Figure S4. Association between seven comorbidities and AIS/AIS recurrence

 The Y-axis shows the odds ratio per standard deviation (SD) and 95% confidence interval 803 (CI) of the seven risk factors (six clinical comorbidities and smoking) in the BBJ $2nd$ cohort. In our dataset, we used HT defined as SBP>140 mmHg, DBP>90 mmHg, or hypertension history, DM inclusive of type 1 diabetes and other diabetes, SM as a current smoker at the time of registration, VD representing myocardial infarction, arteriosclerosis obliterans, stable angina pectoris, unstable angina pectoris, and AF inclusive of atrial flutter. We used the status at the time of registration and history of these comorbidities.

- Abbreviations: HT, hypertension; HL, hyperlipidemia; DM, diabetes; SM, smoking; VD,
- vascular disease; HF, congestive heart failure; AF, atrial fibrillation.

Figure S5. Association between metaGRS and AIS recurrence in patients with or without IPW adjustment

 The y-axis shows the odds ratio per SD and the 95% confidence interval for predicting recurrent AIS. Model 1: age and sex; model 2: age, sex, and seven risk factors; model 3: age, sex, the first 10 principal components (PCs), and seven risk factors. The color represents whether the inverse probability weight (IPW) is adjusted. We applied logistic regression using variables as covariates when the IPW was not adjusted. We replaced 14 missing data 821 on the smoking status to mean values.

Supplementary Tables

In separate spreadsheets S1-15

828 **Consortium authors**

829

830 **BioBank Japan**

- 831 Koichi Matsuda^{1,2}, Yuji Yamanashi³, Yoichi Furukawa⁴, Takayuki Morisaki⁵, Yoshinori 832 Murakami⁶, Yoichiro Kamatani^{2,7}, Kaori Muto⁸, Akiko Nagai⁸, Wataru Obara⁹, Ken Yamaji¹⁰, 833 Kazuhisa Takahashi¹¹, Satoshi Asai^{12,13}, Yasuo Takahashi¹³, Takao Suzuki¹⁴, Nobuaki 834 Sinozaki¹⁴, Hiroki Yamaguchi¹⁵, Shiro Minami¹⁶, Shigeo Murayama¹⁷, Kozo Yoshimori¹⁸, 835 Satoshi Nagayama¹⁹, Daisuke Obata²⁰, Masahiko Higashiyama²¹, Akihide Masumoto²²,
- 836 Yukihiro Koretsune²³

- 838 ¹Laboratory of Genome Technology, Human Genome Center, Institute of Medical Science, 839 The University of Tokyo, Tokyo, Japan.
- 840 ²Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The 841 University of Tokyo, Tokyo, Japan.
- 842 ³Division of Genetics, The Institute of Medical Science, The University of Tokyo, Tokyo, 843 Japan.
- 844 ⁴Division of Clinical Genome Research, Institute of Medical Science, The University of 845 Tokyo, Tokyo, Japan.
- 846 ⁵Division of Molecular Pathology IMSUT Hospital, Department of Internal Medicine Project
- 847 Division of Genomic Medicine and Disease Prevention The Institute of Medical Science The
- 848 University of Tokyo, Tokyo, Japan.
- 849 ⁶Department of Cancer Biology, Institute of Medical Science, The University of Tokyo, 850 Tokyo, Japan.
- 851 ⁷Laboratory of Complex Trait Genomics, Graduate School of Frontier Sciences, The
- 852 University of Tokyo, Tokyo, Japan.

- 853 ⁸Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo,
- 854 Japan.
- 855 ⁹Department of Urology, Iwate Medical University, Iwate, Japan.
- 856 ¹⁰ Department of Internal Medicine and Rheumatology, Juntendo University Graduate School
- 857 of Medicine, Tokyo, Japan.
- 858 ¹¹ Department of Respiratory Medicine, Juntendo University Graduate School of Medicine,
- 859 Tokyo, Japan.
- 12 μ ¹² Division of Pharmacology, Department of Biomedical Science, Nihon University School of
- 861 Medicine, Tokyo, Japan.
- 862 ¹³ Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research Center,
- 863 Nihon University. School of Medicine, Tokyo, Japan.
- 864 ¹⁴ Tokushukai Group, Tokyo, Japan.
- 865 ¹⁵ Hiroki Yamaguchi. Department of Hematology, Nippon Medical School, Tokyo, Japan.
- 866 ¹⁶ Department of Bioregulation, Nippon Medical School, Kawasaki, Japan.
- 867 ¹⁷Shigeo Murayama. Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, 868 Tokyo, Japan.
- 869 ¹⁸Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
- 870 ¹⁹The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, 871 Japan.
- 872 ²⁰Center for Clinical Research and Advanced Medicine, Shiga University of Medical 873 Science, Shiga, Japan.
- 874 ²¹Masahiko Higashiyama. Department of General Thoracic Surgery, Osaka International
- 875 Cancer Institute, Osaka, Japan.
- 876 ²² Iizuka Hospital, Fukuoka, Japan.
- 877 ²³ National Hospital Organization Osaka National Hospital, Osaka, Japan.

878

879 880 881 **MEGASTROKE CONSORTIUM** 882 883 Rainer Malik¹, Ganesh Chauhan², Matthew Traylor³, Muralidharan 884 Sargurupremraj^{4,5}, Yukinori Okada^{6,7,8}, Aniket Mishra^{4,5}, Loes Rutten-Jacobs³, 885 Anne-Katrin Giese⁹, Sander W van der Laan¹⁰, Solveig Gretarsdottir¹¹, Christopher 886 D Anderson^{12,13,14}, Michael Chong¹⁵, Hieab HH Adams^{16,17}, Tetsuro Ago¹⁸, Peter 887 Almgren¹⁹, Philippe Amouyel^{20,21}, Hakan Ay^{13,22}, Traci M Bartz²³, Oscar R 888 Benavente²⁴, Steve Bevan²⁵, Giorgio B Boncoraglio²⁶, Robert D Brown, Jr.²⁷, 889 Adam S Butterworth^{28,29}, Caty Carrera^{30,31}, Cara L Carty^{32,33}, Daniel I 890 Chasman^{34,35}, Wei-Min Chen³⁶, John W Cole³⁷, Adolfo Correa³⁸, Ioana 891 Cotlarciuc³⁹, Carlos Cruchaga^{40,41}, John Danesh^{28,42,43,44}, Paul IW de Bakker^{45,46}, 892 Anita L DeStefano^{47,48}, Marcel den Hoed⁴⁹, Qing Duan⁵⁰, Stefan T Engelter^{51,52}, 893 Guido J Falcone^{53,54}, Rebecca F Gottesman⁵⁵, Raji P Grewal⁵⁶, Vilmundur 894 Gudnason^{57,58}, Stefan Gustafsson⁵⁹, Jeffrey Haessler⁶⁰, Tamara B Harris⁶¹, Ahamad Hassan⁶², Aki S Havulinna^{63,64}, Susan R Heckbert⁶⁵, Elizabeth G Holliday^{66,67}, 896 George Howard⁶⁸, Fang-Chi Hsu⁶⁹, Hyacinth I Hyacinth⁷⁰, M Arfan Ikram¹⁶, Erik 897 Ingelsson^{71,72}, Marguerite R Irvin⁷³, Xueqiu Jian⁷⁴, Jordi Jiménez-Conde⁷⁵, Julie A 898 Johnson^{76,77}, J Wouter Jukema⁷⁸, Masahiro Kanai^{6,7,79}, Keith L Keene^{80,81}, Brett M 899 Kissela⁸², Dawn O Kleindorfer⁸², Charles Kooperberg⁶⁰, Michiaki Kubo⁸³, Leslie A 900 Lange⁸⁴, Carl D Langefeld⁸⁵, Claudia Langenberg⁸⁶, Lenore J Launer⁸⁷, Jin-Moo 901 Lee⁸⁸, Robin Lemmens^{89,90}, Didier Leys⁹¹, Cathryn M Lewis^{92,93}, Wei-Yu Lin^{28,94}, 902 Arne G Lindgren^{95,96}, Erik Lorentzen⁹⁷, Patrik K Magnusson⁹⁸, Jane Maguire⁹⁹, 903 Ani Manichaikul³⁶, Patrick F McArdle¹⁰⁰, James F Meschia¹⁰¹, Braxton D 904 Mitchell^{100,102}, Thomas H Mosley^{103,104}, Michael A Nalls^{105,106}, Toshiharu 905 Ninomiya¹⁰⁷, Martin J O'Donnell^{15,108}, Bruce M Psaty^{109,110,111,112}, Sara L Pulit^{45,113}, 906 Kristiina Rannikmäe^{114,115}, Alexander P Reiner^{65,116}, Kathryn M Rexrode¹¹⁷, 907 Kenneth Rice¹¹⁸, Stephen S Rich³⁶, Paul M Ridker^{34,35}, Natalia S Rost^{9,13}, Peter M 908 Rothwell¹¹⁹, Jerome I Rotter^{120,121}, Tatjana Rundek¹²², Ralph L Sacco¹²², Saori 909 Sakaue^{7,123}, Michele M Sale¹²⁴, Veikko Salomaa⁶³, Bishwa R Sapkota¹²⁵, Reinhold 910 Schmidt¹²⁶, Carsten O Schmidt¹²⁷, Ulf Schminke¹²⁸, Pankaj Sharma³⁹, Agnieszka 911 Slowik¹²⁹, Cathie LM Sudlow^{114,115}, Christian Tanislav¹³⁰, Turgut Tatlisumak^{131,132}, 912 Kent D Taylor^{120,121}, Vincent NS Thijs^{133,134}, Gudmar Thorleifsson¹¹, Unnur Thorsteinsdottir¹¹, Steffen Tiedt¹, Stella Trompet¹³⁵, Christophe Tzourio^{5,136,137}, 913 Thorsteinsdottir¹¹, Steffen Tiedt¹, Stella Trompet¹³⁵, Christophe Tzourio^{5,136,137}, 914 Cornelia M van Duijn^{138,139}, Matthew Walters¹⁴⁰, Nicholas J Wareham⁸⁶, Sylvia 915 Wassertheil-Smoller¹⁴¹, James G Wilson¹⁴², Kerri L Wiggins¹⁰⁹, Qiong Yang⁴⁷, 916 Salim Yusuf¹⁵, Najaf Amin¹⁶, Hugo S Aparicio^{48,185}, Donna K Arnett¹⁸⁶, John 917 Attia¹⁸⁷, Alexa S Beiser^{47,48}, Claudine Berr¹⁸⁸, Julie E Buring^{34,35}, Mariana 918 Bustamante¹⁸⁹, Valeria Caso¹⁹⁰, Yu-Ching Cheng¹⁹¹, Seung Hoan Choi^{48,192}, 919 Ayesha Chowhan^{48,185}, Natalia Cullell³¹, Jean-François Dartigues^{193,194}, Hossein 920 Delavaran^{95,96}, Pilar Delgado¹⁹⁵, Marcus Dörr^{196,197}, Gunnar Engström¹⁹, Ian 921 Ford¹⁹⁸, Wander S Gurpreet¹⁹⁹, Anders Hamsten^{200,201}, Laura Heitsch²⁰², Atsushi 922 Hozawa²⁰³, Laura Ibanez²⁰⁴, Andreea Ilinca^{95,96}, Martin Ingelsson²⁰⁵, Motoki 923 Iwasaki²⁰⁶, Rebecca D Jackson²⁰⁷, Katarina Jood²⁰⁸, Pekka Jousilahti⁶³, Sara 924 Kaffashian^{4,5}, Lalit Kalra²⁰⁹, Masahiro Kamouchi²¹⁰, Takanari Kitazono²¹¹, Olafur 925 Kjartansson²¹², Manja Kloss²¹³, Peter J Koudstaal²¹⁴, Jerzy Krupinski²¹⁵, Daniel L 926 Labovitz²¹⁶, Cathy C Laurie¹¹⁸, Christopher R Levi²¹⁷, Linxin Li²¹⁸, Lars Lind²¹⁹,

927 Cecilia M Lindgren^{220,221}, Vasileios Lioutas^{48,222}, Yong Mei Liu²²³, Oscar L
928 Lopez²²⁴, Hirata Makoto²²⁵, Nicolas Martinez-Majander¹⁷², Koichi Matsuda²²⁵, 928 Lopez²²⁴, Hirata Makoto²²⁵, Nicolas Martinez-Majander¹⁷², Koichi Matsuda²²⁵, 929 Naoko Minegishi²⁰³, Joan Montaner²²⁶, Andrew P Morris^{227,228}, Elena Muiño³¹, 930 Martina Müller-Nurasyid^{229,230,231}, Bo Norrving^{95,96}, Soichi Ogishima²⁰³, Eugenio 931 A Parati²³², Leema Reddy Peddareddygari⁵⁶, Nancy L Pedersen^{98,233}, Joanna 932 Pera¹²⁹, Markus Perola^{63,234}, Alessandro Pezzini²³⁵, Silvana Pileggi²³⁶, Raquel 933 Rabionet²³⁷, Iolanda Riba-Llena³⁰, Marta Ribasés²³⁸, Jose R Romero^{48,185}, Jaume 934 Roquer^{239,240}, Anthony G Rudd^{241,242}, Antti-Pekka Sarin^{243,244}, Ralhan Sarju¹⁹⁹, 935 Chloe Sarnowski^{47,48}, Makoto Sasaki²⁴⁵, Claudia L Satizabal^{48,185}, Mamoru 936 Satoh²⁴⁵, Naveed Sattar²⁴⁶, Norie Sawada²⁰⁶, Gerli Sibolt¹⁷², Ásgeir Sigurdsson²⁴⁷, 937 Albert Smith²⁴⁸, Kenji Sobue²⁴⁵, Carolina Soriano-Tárraga²⁴⁰, Tara Stanne²⁴⁹, O 938 Colin Stine²⁵⁰, David J Stott²⁵¹, Konstantin Strauch^{229,252}, Takako Takai²⁰³, Hideo 939 Tanaka^{253,254}, Kozo Tanno²⁴⁵, Alexander Teumer²⁵⁵, Liisa Tomppo¹⁷², Nuria P 940 Torres-Aguila³¹, Emmanuel Touze^{256,257}, Shoichiro Tsugane²⁰⁶, Andre G 941 Uitterlinden²⁵⁸, Einar M Valdimarsson²⁵⁹, Sven J van der Lee¹⁶, Henry Völzke²⁵⁵, 942 Kenji Wakai²⁵³, David Weir²⁶⁰, Stephen R Williams²⁶¹, Charles DA Wolfe^{241,242}, 943 Quenna Wong¹¹⁸, Huichun Xu¹⁹¹, Taiki Yamaji²⁰⁶, Dharambir K Sanghera^{125,169,170}, 944 Olle Melander¹⁹, Christina Jern¹⁷¹, Daniel Strbian^{172,173}, Israel Fernandez-945 Cadenas^{31,30}, W T Longstreth, Jr^{65,174}, Arndt Rolfs¹⁷⁵, Jun Hata¹⁰⁷, Daniel Woo⁸², 946 Jonathan Rosand^{12,13,14}, Guillaume Pare¹⁵, Jemma C Hopewell¹⁷⁶, Danish Saleheen¹⁷⁷, Kari Stefansson^{11,178}, Bradford B Worrall¹⁷⁹, Steven J Kittner³⁷, Saleheen¹⁷⁷, Kari Stefansson^{11,178}, Bradford B Worrall¹⁷⁹, Steven J Kittner³⁷, 948 Sudha Seshadri^{48,180}, Myriam Fornage^{74,181}, Hugh S Markus³, Joanna MM Howson²⁸, Yoichiro Kamatani^{6,182}, Stephanie Debette^{4,5}, Martin Dichgans^{1,183,184} 950 951 ¹Institute for Stroke and Dementia Research (ISD), University Hospital, LMU 952 Munich, Munich, Germany 953 ² Centre for Brain Research, Indian Institute of Science, Bangalore, India 954 ³Stroke Research Group, Division of Clinical Neurosciences, University of 955 Cambridge, UK 956 ⁴INSERM U1219 Bordeaux Population Health Research Center, Bordeaux, France 957 ⁵University of Bordeaux, Bordeaux, France 958 ⁶Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical 959 Sciences, Yokohama, Japan 960 ⁷Department of Statistical Genetics, Osaka University Graduate School of 961 Medicine, Osaka, Japan 962 ⁸Laboratory of Statistical Immunology, Immunology Frontier Research Center 963 (WPI-IFReC), Osaka University, Suita, Japan. 964 ⁹Department of Neurology, Massachusetts General Hospital, Harvard Medical 965 School, Boston, MA, USA 966 10 Laboratory of Experimental Cardiology, Division of Heart and Lungs, University 967 Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands 968 11 deCODE genetics/AMGEN inc, Reykjavik, Iceland 12^1 Penter for Genomic Medicine, Massachusetts General Hospital (MGH), Boston, 970 MA, USA 971 13 J. Philip Kistler Stroke Research Center, Department of Neurology, MGH, 972 Boston, MA, USA 14 Program in Medical and Population Genetics, Broad Institute, Cambridge, MA,

- 974 USA
- 975 ¹⁵ Population Health Research Institute, McMaster University, Hamilton, Canada
- 976 ¹⁶Department of Epidemiology, Erasmus University Medical Center, Rotterdam,
- Netherlands
- 978 17 Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, Netherlands
- Pepartment of Medicine and Clinical Science, Graduate School of Medical
- Sciences, Kyushu University, Fukuoka, Japan
- ¹⁹ Department of Clinical Sciences, Lund University, Malmö, Sweden
- 983 ²⁰Univ. Lille, Inserm, Institut Pasteur de Lille, LabEx DISTALZ-UMR1167, Risk
- factors and molecular determinants of aging-related diseases, F-59000 Lille,
- France
- 986 21 Centre Hosp. Univ Lille, Epidemiology and Public Health Department, F-59000 Lille, France
- 988 22 AA Martinos Center for Biomedical Imaging, Department of Radiology,
- Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- ²³ Cardiovascular Health Research Unit, Departments of Biostatistics and Medicine,
- University of Washington, Seattle, WA, USA
- 24 992 24 Division of Neurology, Faculty of Medicine, Brain Research Center, University
993 of British Columbia, Vancouver, Canada
- of British Columbia, Vancouver, Canada
- 994 25 School of Life Science, University of Lincoln, Lincoln, UK
- 995 ²⁶Department of Cerebrovascular Diseases, Fondazione IRCCS Istituto
- Neurologico "Carlo Besta", Milano, Italy
- 997 ²⁷ Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA
- 28 998 ²⁸ MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and
- Primary Care, University of Cambridge, Cambridge, UK
- 29 The National Institute for Health Research Blood and Transplant Research Unit
- in Donor Health and Genomics, University of Cambridge, UK
- ³⁰ Neurovascular Research Laboratory, Vall d'Hebron Institut of Research,
- Neurology and Medicine Departments-Universitat Autònoma de Barcelona, Vall
- d'Hebrón Hospital, Barcelona, Spain
- ³¹ Stroke Pharmacogenomics and Genetics, Fundacio Docència i Recerca
- MutuaTerrassa, Terrassa, Spain
- ³² Children's Research Institute, Children's National Medical Center, Washington, DC, USA
- ³³ Center for Translational Science, George Washington University, Washington, DC, USA
- ³⁴ Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA
- 1013 ³⁵ Harvard Medical School, Boston, MA, USA
- ³⁶ 26 1014 ³⁶ Center for Public Health Genomics, Department of Public Health Sciences,
- University of Virginia, Charlottesville, VA, USA
- Department of Neurology, University of Maryland School of Medicine and
- Baltimore VAMC, Baltimore, MD, USA
- 1018 ³⁸ Departments of Medicine, Pediatrics and Population Health Science, University
- of Mississippi Medical Center, Jackson, MS, USA
- ³⁹ Institute of Cardiovascular Research, Royal Holloway University of London,
- UK & Ashford and St Peters Hospital, Surrey UK
- 40 Department of Psychiatry, The Hope Center Program on Protein Aggregation and
- Neurodegeneration (HPAN),Washington University, School of Medicine, St. Louis,
- MO, USA

- 1025 ⁴¹ Department of Developmental Biology, Washington University School of
- 1026 Medicine, St. Louis, MO, USA
- 1027 ⁴² NIHR Blood and Transplant Research Unit in Donor Health and Genomics,
- 1028 Department of Public Health and Primary Care, University of Cambridge, 1029 Cambridge, UK
-
- 1030 ⁴³Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus,
- 1031 Hinxton, Cambridge, UK
- 1032 ⁴⁴ British Heart Foundation, Cambridge Centre of Excellence, Department of
- 1033 Medicine, University of Cambridge, Cambridge, UK
- ⁴⁵ 1034 Department of Medical Genetics, University Medical Center Utrecht, Utrecht, 1035 Netherlands
- 1036 ⁴⁶ Department of Epidemiology, Julius Center for Health Sciences and Primary
- 1037 Care, University Medical Center Utrecht, Utrecht, Netherlands
- 1038 ⁴⁷ Boston University School of Public Health, Boston, MA, USA
- 1039 ⁴⁸ Framingham Heart Study, Framingham, MA, USA
- 1040 ⁴⁹ Department of Immunology, Genetics and Pathology and Science for Life
- 1041 Laboratory, Uppsala University, Uppsala, Sweden
- ⁵⁰ Department of Genetics, University of North Carolina, Chapel Hill, NC, USA
- ⁵¹ Department of Neurology and Stroke Center, Basel University Hospital,
- 1044 Switzerland
- 1045 ⁵² Neurorehabilitation Unit, University and University Center for Medicine of
- 1046 Aging and Rehabilitation Basel, Felix Platter Hospital, Basel, Switzerland
- ⁵³ Department of Neurology, Yale University School of Medicine, New Haven, CT, 1048 USA
- 1049 54 Program in Medical and Population Genetics. The Broad Institute of Harvard and 1050 MIT, Cambridge, MA, USA
- 1051 ⁵⁵ Department of Neurology, Johns Hopkins University School of Medicine,
- 1052 Baltimore, MD, USA
- ⁵⁶ 1053 Neuroscience Institute, SF Medical Center, Trenton, NJ, USA
- 1054 ⁵⁷ Icelandic Heart Association Research Institute, Kopavogur, Iceland
- 1055 ⁵⁸ University of Iceland, Faculty of Medicine, Reykjavik, Iceland
- ⁵⁹ Department of Medical Sciences, Molecular Epidemiology and Science for Life
- 1057 Laboratory, Uppsala University, Uppsala, Sweden
- 1058 ⁶⁰ Division of Public Health Sciences, Fred Hutchinson Cancer Research Center,
- 1059 Seattle, WA, USA
- ⁶¹ Laboratory of Epidemiology and Population Science, National Institute on Aging, 1061 National Institutes of Health, Bethesda, MD, USA
- 1062 ⁶²Department of Neurology, Leeds General Infirmary, Leeds Teaching Hospitals
- 1063 NHS Trust, Leeds, UK
- 1064 ⁶³ National Institute for Health and Welfare, Helsinki, Finland
- 1065 64 FIMM Institute for Molecular Medicine Finland, Helsinki, Finland
- 1066 ⁶⁵Department of Epidemiology, University of Washington, Seattle, WA, USA
- 1067 ⁶⁶ Public Health Stream, Hunter Medical Research Institute, New Lambton,
- 1068 Australia
- 1069 ⁶⁷ Faculty of Health and Medicine, University of Newcastle, Newcastle, Australia
- 1070 ⁶⁸ School of Public Health, University of Alabama at Birmingham, Birmingham, AL, 1071 USA
- ⁶⁹ Department of Biostatistical Sciences, Wake Forest School of Medicine,
- 1073 Winston-Salem, NC, USA

- ⁷⁰ Aflac Cancer and Blood Disorder Center, Department of Pediatrics, Emory
- 1075 University School of Medicine, Atlanta, GA, USA
- 1076 ⁷¹ Department of Medicine, Division of Cardiovascular Medicine, Stanford
- 1077 University School of Medicine, CA, USA
- ⁷² Department of Medical Sciences, Molecular Epidemiology and Science for Life 1079 Laboratory, Uppsala University, Uppsala, Sweden
- 1080 73 Epidemiology, School of Public Health, University of Alabama at Birmingham, 1081 USA
- ⁷⁴ Brown Foundation Institute of Molecular Medicine, University of Texas Health 1083 Science Center at Houston, Houston, TX, USA
- 1084 ⁷⁵ Neurovascular Research Group (NEUVAS), Neurology Department, Institut
- 1085 Hospital del Mar d'Investigació Mèdica, Universitat Autònoma de Barcelona, 1086 Barcelona, Spain
- 1087 ⁷⁶ Department of Pharmacotherapy and Translational Research and Center for
- 1088 Pharmacogenomics, University of Florida, College of Pharmacy, Gainesville, FL, 1089 USA
- 1090 $⁷⁷$ Division of Cardiovascular Medicine, College of Medicine, University of Florida,</sup> 1091 Gainesville, FL, USA
- 1092 ⁷⁸ Department of Cardiology, Leiden University Medical Center, Leiden, the 1093 Netherlands
-
- 1094 ⁷⁹ Program in Bioinformatics and Integrative Genomics, Harvard Medical School, 1095 Boston, MA, USA
- 1096 ⁸⁰ Department of Biology, East Carolina University, Greenville, NC, USA
- 1097 ⁸¹ Center for Health Disparities, East Carolina University, Greenville, NC, USA
- 1098 82 University of Cincinnati College of Medicine, Cincinnati, OH, USA
- 1099 ⁸³RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
- 1100 ⁸⁴ Department of Medicine, University of Colorado Denver, Anschutz Medical
- 1101 Campus, Aurora, CO, USA
- 1102 ⁸⁵ Center for Public Health Genomics and Department of Biostatistical Sciences,
- 1103 Wake Forest School of Medicine, Winston-Salem, NC, USA
- 1104 ⁸⁶MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
- 1105 Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, UK
- 1106 ⁸⁷ Intramural Research Program, National Institute on Aging, National Institutes of 1107 Health, Bethesda, MD, USA
- 1108 ⁸⁸ Department of Neurology, Radiology, and Biomedical Engineering, Washington
- 1109 University School of Medicine, St. Louis, MO, USA
- 1110 89 KU Leuven University of Leuven, Department of
- 1111 Neurosciences, Experimental Neurology, Leuven, Belgium
- 1112 $\frac{90}{112}$ VIB Center for Brain & Disease Research, University Hospitals Leuven,
- 1113 Department of Neurology, Leuven, Belgium
- 1114 ⁹¹ Univ.-Lille, INSERM U 1171. CHU Lille. Lille, France
- ⁹² Department of Medical and Molecular Genetics, King's College London, London, 1116 UK
- 1117 93 SGDP Centre, Institute of Psychiatry, Psychology & Neuroscience, King's
- 1118 College London, London, UK
- ⁹⁴ Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle
- 1120 University, Newcastle, UK
- ⁹⁵ Department of Clinical Sciences Lund, Neurology, Lund University, Lund,
- 1122 Sweden
- ⁹⁶ Department of Neurology and Rehabilitation Medicine, Skåne University
- Hospital, Lund, Sweden
- ⁹⁷ Bioinformatics Core Facility, University of Gothenburg, Gothenburg, Sweden
- ⁹⁸ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- ⁹⁹ University of Technology Sydney, Faculty of Health, Ultimo, Australia
- 100 Department of Medicine, University of Maryland School of Medicine, MD, USA
- 1130 ¹⁰¹Department of Neurology, Mayo Clinic, Jacksonville, FL, USA
- 102 Geriatrics Research and Education Clinical Center, Baltimore Veterans
- Administration Medical Center, Baltimore, MD, USA
- 103 Division of Geriatrics, School of Medicine, University of Mississippi Medical
- Center, Jackson, MS, USA
- 104 Memory Impairment and Neurodegenerative Dementia Center, University of Mississippi Medical Center, Jackson, MS, USA
- 1137 ¹⁰⁵ Laboratory of Neurogenetics, National Institute on Aging, National institutes of
- Health, Bethesda, MD, USA
- 1139 ¹⁰⁶ Data Tecnica International, Glen Echo MD, USA
- 107 Department of Epidemiology and Public Health, Graduate School of Medical
- Sciences, Kyushu University, Fukuoka, Japan
- ¹⁰⁸ Clinical Research Facility, Department of Medicine, NUI Galway, Galway, Ireland
-
- ¹⁰⁹ Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA
- 110 Department of Epidemiology, University of Washington, Seattle, WA, USA
- 111 Department of Health Services, University of Washington, Seattle, WA, USA
- 1148 ¹¹² Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA
- 1149 ¹¹³ Brain Center Rudolf Magnus, Department of Neurology, University Medical
- Center Utrecht, Utrecht, The Netherlands
- 114 Usher Institute of Population Health Sciences and Informatics, University of
- Edinburgh, Edinburgh, UK
- 115 Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- 1154 ¹¹⁶ Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
- 117 Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
- 1157 ¹¹⁸ Department of Biostatistics, University of Washington, Seattle, WA, USA
- 1158 ¹¹⁹ Nuffield Department of Clinical Neurosciences, University of Oxford, UK
- 1159 Institute for Translational Genomics and Population Sciences, Los Angeles
- Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA
- 1162 ¹²¹ Division of Genomic Outcomes, Department of Pediatrics, Harbor-UCLA
- Medical Center, Torrance, CA, USA
- 1164 Department of Neurology, Miller School of Medicine, University of Miami,
- Miami, FL, USA
- 1166 Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
- ¹²⁴ Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA
- 125 Department of Pediatrics, College of Medicine, University of Oklahoma Health
- Sciences Center, Oklahoma City, OK, USA
- ¹²⁶Department of Neurology, Medical University of Graz, Graz, Austria
- 1173 ¹²⁷ University Medicine Greifswald, Institute for Community Medicine, SHIP-KEF,
- Greifswald, Germany
- ¹²⁸ University Medicine Greifswald, Department of Neurology, Greifswald,
- Germany
- ¹²⁹ Department of Neurology, Jagiellonian University, Krakow, Poland
- ¹³⁰ Department of Neurology, Justus Liebig University, Giessen, Germany
- 1179 ¹³¹ Department of Clinical Neurosciences/Neurology, Institute of Neuroscience and
- Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg,
- Sweden
- ¹³² Sahlgrenska University Hospital, Gothenburg, Sweden
- 1183 ¹³³ Stroke Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Australia
- ¹³⁴ Austin Health, Department of Neurology, Heidelberg, Australia
- 1186 ¹³⁵ Department of Internal Medicine, Section Gerontology and Geriatrics, Leiden
- University Medical Center, Leiden, the Netherlands
- 1188 ¹³⁶INSERM U1219, Bordeaux, France
- 137 Department of Public Health, Bordeaux University Hospital, Bordeaux, France
- ¹³⁸ Genetic Epidemiology Unit, Department of Epidemiology, Erasmus University
- Medical Center Rotterdam, Netherlands
- 1192 ¹³⁹ Center for Medical Systems Biology, Leiden, Netherlands
- ¹⁴⁰ School of Medicine, Dentistry and Nursing at the University of Glasgow,
- Glasgow, UK
- 1195 ¹⁴¹ Department of Epidemiology and Population Health, Albert Einstein College of Medicine, NY, USA
- 142 Department of Physiology and Biophysics, University of Mississippi Medical
- Center, Jackson, MS, USA
- 143 A full list of members and affiliations appears in the Supplementary Note
- 1200 ¹⁴⁴ Department of Human Genetics, McGill University, Montreal, Canada
- 145 Department of Pathophysiology, Institute of Biomedicine and Translation Medicine, University of Tartu, Tartu, Estonia
- 1203 ¹⁴⁶ Department of Cardiac Surgery, Tartu University Hospital, Tartu, Estonia 1204 ¹⁴⁷ Clinical Gene Networks AB, Stockholm, Sweden
- 148 Department of Genetics and Genomic Sciences, The Icahn Institute for
- Genomics and Multiscale Biology Icahn School of Medicine at Mount Sinai, New
- York, NY , USA
- ¹⁴⁹ Department of Pathophysiology, Institute of Biomedicine and Translation
- Medicine, University of Tartu, Biomeedikum, Tartu, Estonia
- 1210 ¹⁵⁰ Integrated Cardio Metabolic Centre, Department of Medicine, Karolinska
- Institutet, Karolinska Universitetssjukhuset, Huddinge, Sweden.
- 1212 ¹⁵¹ Clinical Gene Networks AB, Stockholm, Sweden
- 1213 ¹⁵² Sorbonne Universités, UPMC Univ. Paris 06, INSERM, UMR_S 1166, Team
- Genomics & Pathophysiology of Cardiovascular Diseases, Paris, France
- 1215 ¹⁵³ICAN Institute for Cardiometabolism and Nutrition, Paris, France
- 154 Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA
- 155 Group Health Research Institute, Group Health Cooperative, Seattle, WA, USA
- 1219 ¹⁵⁶ Seattle Epidemiologic Research and Information Center, VA Office of Research and Development, Seattle, WA, USA
- 1221 ¹⁵⁷ Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA,
- USA
- 1223 ¹⁵⁸ Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway 15% Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore ¹⁶⁰ National Heart and Lung Institute, Imperial College London, London, UK 1228 ¹⁶¹ Department of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan 162 Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA 1232 ¹⁶³ Department of Cardiology, University Medical Center Groningen, University of Groningen, Netherlands 1234 ¹⁶⁴MRC-PHE Centre for Environment and Health, School of Public Health, Department of Epidemiology and Biostatistics, Imperial College London, London, UK 1237 ¹⁶⁵ Department of Epidemiology and Biostatistics, Imperial College London, London, UK 1239 166 Department of Cardiology, Ealing Hospital NHS Trust, Southall, UK 1240 ¹⁶⁷ National Heart, Lung and Blood Research Institute, Division of Intramural Research, Population Sciences Branch, Framingham, MA, USA ¹⁶⁸A full list of members and affiliations appears at the end of the manuscript 1243 ¹⁶⁹ Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA 1245 ¹⁷⁰ Oklahoma Center for Neuroscience, Oklahoma City, OK, USA 171 Department of Pathology and Genetics, Institute of Biomedicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden 1248 ¹⁷² Department of Neurology, Helsinki University Hospital, Helsinki, Finland 1249 ¹⁷³ Clinical Neurosciences, Neurology, University of Helsinki, Helsinki, Finland 1250 ¹⁷⁴ Department of Neurology, University of Washington, Seattle, WA, USA 1251 ¹⁷⁵ Albrecht Kossel Institute, University Clinic of Rostock, Rostock, Germany ¹⁷⁶ Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK 1254 ¹⁷⁷ Department of Genetics, Perelman School of Medicine, University of Pennsylvania, PA, USA ¹⁷⁸ Faculty of Medicine, University of Iceland, Reykjavik, Iceland 179 Departments of Neurology and Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA ¹⁸⁰ Department of Neurology, Boston University School of Medicine, Boston, MA, USA 1261 ¹⁸¹ Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA ¹⁸² Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan 1265 Munich Cluster for Systems Neurology (SyNergy), Munich, Germany 1266 ¹⁸⁴ German Center for Neurodegenerative Diseases (DZNE), Munich, Germany 1267 ¹⁸⁵ Boston University School of Medicine, Boston, MA, USA ¹⁸⁶ University of Kentucky College of Public Health, Lexington, KY, USA 1269 ¹⁸⁷ University of Newcastle and Hunter Medical Research Institute, New Lambton,
- Australia
- ¹⁸⁸ Univ. Montpellier, Inserm, U1061, Montpellier, France
- ¹⁸⁹ Centre for Research in Environmental Epidemiology, Barcelona, Spain

- 1273 ¹⁹⁰ Department of Neurology, Università degli Studi di Perugia, Umbria, Italy
- 1274 ¹⁹¹ Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
- 192 Broad Institute, Cambridge, MA, USA
- 1277 ¹⁹³ Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR
- 1219, Bordeaux, France
- 194 Bordeaux University Hospital, Department of Neurology, Memory Clinic,
- Bordeaux, France
- 1281 ¹⁹⁵ Neurovascular Research Laboratory. Vall d'Hebron Institut of Research,
- Neurology and Medicine Departments-Universitat Autònoma de Barcelona. Vall
- d'Hebrón Hospital, Barcelona, Spain
- 196 University Medicine Greifswald, Department of Internal Medicine B,
- Greifswald, Germany
- 1286 197 DZHK, Greifswald, Germany
- 1287 ¹⁹⁸ Robertson Center for Biostatistics, University of Glasgow, Glasgow, UK
- 1288 ¹⁹⁹ Hero DMC Heart Institute, Dayanand Medical College & Hospital, Ludhiana,
- India
- 200 Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska
- Institutet, Stockholm, Sweden
- ²⁰¹ Karolinska Institutet, Stockholm, Sweden
- $202 \text{Division of Energy Medicine, and Department of Neurology, Washington}$
- University School of Medicine, St. Louis, MO, USA
- ²⁰³ Tohoku Medical Megabank Organization, Sendai, Japan
- 204 Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA
- 1298 ²⁰⁵Department of Public Health and Caring Sciences / Geriatrics, Uppsala
- University, Uppsala, Sweden
- ²⁰⁶ Epidemiology and Prevention Group, Center for Public Health Sciences,
- National Cancer Center, Tokyo, Japan
- ²⁰⁷ Department of Internal Medicine and the Center for Clinical and Translational
- Science, The Ohio State University, Columbus, OH, USA
- ²⁰⁸ Institute of Neuroscience and Physiology, the Sahlgrenska Academy at
- University of Gothenburg, Goteborg, Sweden
- 1306 ²⁰⁹ Department of Basic and Clinical Neurosciences, King's College London, London, UK
- 1308 ²¹⁰ Department of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University, Japan
- 211 Department of Medicine and Clinical Science, Graduate School of Medical
- Sciences, Kyushu University, Japan
- 1312 ²¹² Landspitali National University Hospital, Departments of Neurology &
- Radiology, Reykjavik, Iceland
- 1314 ²¹³ Department of Neurology, Heidelberg University Hospital, Germany
- 1315 ²¹⁴ Department of Neurology, Erasmus University Medical Center
- ²¹⁵ Hospital Universitari Mutua Terrassa, Terrassa (Barcelona), Spain
- ²¹⁶ Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA
- 2^{17} John Hunter Hospital, Hunter Medical Research Institute and University of
- Newcastle, Newcastle, NSW, Australia
- 1321 ²¹⁸ Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical
- Neurosciences, University of Oxford, UK
- 1323 ²¹⁹ Department of Medical Sciences, Uppsala University, Uppsala, Sweden
- 1324 ²²⁰ Genetic and Genomic Epidemiology Unit, Wellcome Trust Centre for Human
- 1325 Genetics, University of Oxford, Oxford, UK
- 1326 ²²¹ The Wellcome Trust Centre for Human Genetics, Oxford, UK
- 1327 ²²² Beth Israel Deaconess Medical Center, Boston, MA, USA
- 1328 ²²³Wake Forest School of Medicine, Wake Forest, NC, USA
- 1329 224 Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
- 1330 ²²⁵ BioBank Japan, Laboratory of Clinical Sequencing, Department of
- 1331 Computational biology and medical Sciences, Graduate school of Frontier Sciences,
- 1332 The University of Tokyo, Tokyo, Japan
- 1333 ²²⁶ Neurovascular Research Laboratory, Vall d'Hebron Institut of Research,
- 1334 Neurology and Medicine Departments-Universitat Autònoma de Barcelona. Vall
- 1335 d'Hebrón Hospital, Barcelona, Spain
- 1336 227 Department of Biostatistics, University of Liverpool, Liverpool, UK
- 1337 ²²⁸Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
- 1338 ²²⁹ Institute of Genetic Epidemiology, Helmholtz Zentrum München German
- 1339 Research Center for Environmental Health, Neuherberg, Germany
- ²³⁰ 1340 Department of Medicine I, Ludwig-Maximilians-Universität, Munich, Germany
- 1341 ²³¹DZHK (German Centre for Cardiovascular Research), partner site Munich Heart 1342 Alliance, Munich, Germany
- ²³² 1343 Department of Cerebrovascular Diseases, Fondazione IRCCS Istituto
- 1344 Neurologico "Carlo Besta", Milano, Italy
- ²³³ 1345 Karolinska Institutet, MEB, Stockholm, Sweden
- ²³⁴ University of Tartu, Estonian Genome Center, Tartu, Estonia, Tartu, Estonia
- ²³⁵ Department of Clinical and Experimental Sciences, Neurology Clinic,
- 1348 University of Brescia, Italy
- ²³⁶ Translational Genomics Unit, Department of Oncology, IRCCS Istituto di
- 1350 Ricerche Farmacologiche Mario Negri, Milano, Italy
- 1351 237 Department of Genetics, Microbiology and Statistics, University of Barcelona, 1352 Barcelona, Spain
- ²³⁸ Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addictions,
- 1354 Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona,
- 1355 Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, 1356 Spain
- 1357 239 Department of Neurology, IMIM-Hospital del Mar, and Universitat Autònoma 1358 de Barcelona, Spain
- 1359 ²⁴⁰ IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- 1360 ²⁴¹ National Institute for Health Research Comprehensive Biomedical Research
- 1361 Centre, Guy's & St. Thomas' NHS Foundation Trust and King's College London,
- 1362 London, UK
- 1363 ²⁴² Division of Health and Social Care Research, King's College London, London, 1364 UK
- 1365 ²⁴³ FIMM-Institute for Molecular Medicine Finland, Helsinki, Finland
- 1366 ²⁴⁴ THL-National Institute for Health and Welfare, Helsinki, Finland
- 1367 ²⁴⁵ Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Iwate, 1368 Japan
- ²⁴⁶ BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, Glasgow, 1370 UK
-
- 1371 ²⁴⁷ deCODE Genetics/Amgen, Inc., Reykjavik, Iceland
- 1372 248 Icelandic Heart Association, Reykjavik, Iceland

- ²⁴⁹ Institute of Biomedicine, the Sahlgrenska Academy at University of Gothenburg,
- Goteborg, Sweden
- ²⁵⁰ Department of Epidemiology, University of Maryland School of Medicine,
- Baltimore, MD, USA
- ²⁵¹ Institute of Cardiovascular and Medical Sciences, Faculty of Medicine,
- University of Glasgow, Glasgow, UK
- 1379 ²⁵² Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich.
- Germany
- 1381 ²⁵³ Division of Epidemiology and Prevention, Aichi Cancer Center Research
- Institute, Nagoya, Japan
- ²⁵⁴ Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
- 1385 ²⁵⁵University Medicine Greifswald, Institute for Community Medicine, SHIP-KEF, Greifswald, Germany
- ²⁵⁶ Department of Neurology, Caen University Hospital, Caen, France
- 1388 ²⁵⁷University of Caen Normandy, Caen, France
- 1389 ²⁵⁸ Department of Internal Medicine, Erasmus University Medical Center,
- Rotterdam, Netherlands
- 1391 259 Landspitali University Hospital, Reykjavik, Iceland
- ²⁶⁰ Survey Research Center, University of Michigan, Ann Arbor, MI, USA
- ²⁶¹ University of Virginia Department of Neurology, Charlottesville, VA, USA
-
-